- Home
- ELDN vs PLX Comparison
ELDN vs PLX Comparison
Compare ELDN & PLX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ELDN
- PLX
- Stock Information
- Founded
- ELDN 2004
- PLX 1993
- Country
- ELDN United States
- PLX United States
- Employees
- ELDN N/A
- PLX N/A
- Industry
- ELDN Biotechnology: Pharmaceutical Preparations
- PLX Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- ELDN Health Care
- PLX Health Care
- Exchange
- ELDN Nasdaq
- PLX Nasdaq
- Market Cap
- ELDN 178.4M
- PLX 160.2M
- IPO Year
- ELDN N/A
- PLX 1998
- Fundamental
- Price
- ELDN $2.89
- PLX $1.73
- Analyst Decision
- ELDN Strong Buy
- PLX Strong Buy
- Analyst Count
- ELDN 1
- PLX 1
- Target Price
- ELDN $16.00
- PLX $15.00
- AVG Volume (30 Days)
- ELDN 160.2K
- PLX 1.0M
- Earning Date
- ELDN 05-20-2025
- PLX 05-09-2025
- Dividend Yield
- ELDN N/A
- PLX N/A
- EPS Growth
- ELDN N/A
- PLX N/A
- EPS
- ELDN N/A
- PLX 0.04
- Revenue
- ELDN N/A
- PLX $59,764,000.00
- Revenue This Year
- ELDN N/A
- PLX $65.02
- Revenue Next Year
- ELDN N/A
- PLX $57.34
- P/E Ratio
- ELDN N/A
- PLX $40.01
- Revenue Growth
- ELDN N/A
- PLX 0.18
- 52 Week Low
- ELDN $2.00
- PLX $0.82
- 52 Week High
- ELDN $5.54
- PLX $3.10
- Technical
- Relative Strength Index (RSI)
- ELDN 40.93
- PLX 27.30
- Support Level
- ELDN $2.85
- PLX $2.70
- Resistance Level
- ELDN $3.51
- PLX $2.93
- Average True Range (ATR)
- ELDN 0.27
- PLX 0.21
- MACD
- ELDN -0.01
- PLX -0.08
- Stochastic Oscillator
- ELDN 5.63
- PLX 0.36
About ELDN Eledon Pharmaceuticals Inc.
Eledon Pharmaceuticals Inc is a clinical-stage biotechnology company. The firm is focused on transplantation and autoimmune diseases. It targets the CD40L pathway to develop potential treatments for patients living with an autoimmune disease, patients requiring an organ or cell-based transplant, and patients living with ALS. The company's compound in development is tegoprubart, an IgG1, an anti-CD40L antibody with high affinity for the CD40 Ligand, a well-validated biological target that has broad therapeutic potential.
About PLX Protalix BioTherapeutics Inc. (DE)
Protalix BioTherapeutics Inc is a biopharmaceutical company focused on the development and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx protein expression system or ProCellEx. It has developed taliglucerase alfa for the treatment of Gaucher disease. The company's products also treat diseases like Fabry disease and cystic fibrosis. The company's primary sources of revenue include its sales of BioManguinhos alfataliglicerase in Brazil and of drug substances to Pfizer under its Amended Pfizer Agreement. The company's pipeline consists of ELFABRIO, Uricase, and Long Acting DNase I.